Paschalis Evangelidis: A New Way to Treat iTTP by Targeting the Autoimmune Process
Paschalis Evangelidis, Former Teaching Assistant at Aristotle University of Thessaloniki (AUTH) shared a post on LinkedIn about a recent article he and Eleni Gavriilaki co-authored, adding:
”Excited to share our insightful commentary on immune-mediated thrombotic thrombocytopenic purpura (iTTP):
This piece highlights a promising shift in how we think about iTTP – not just managing acute episodes, but targeting the underlying autoimmune process.
A novel approach using red blood cells to deliver ADAMTS13 antigens in an ‘immune-silent’ way could help induce immune tolerance and reduce relapses.
While still early, this strategy opens the door to more precise, long-term solutions beyond conventional immunosuppression.
A small but meaningful step toward solving another piece of the TTP puzzle.”
Title: Solving another piece of the thrombotic thrombocytopenic purpura puzzle?
Authors: Paschalis Evangelidis, Eleni Gavriilaki
Stay updated on all scientific advances with Hemostasis Today.
-
May 13, 2026, 17:38Rohit Sankar J. Snscphysio: Recognizing the Clot Before It Becomes Life-Threatening
-
May 13, 2026, 16:41Seema Dawood: When Elevated Platelets Signal a Myeloproliferative Neoplasm
-
May 13, 2026, 16:38Kari Tikkinen: Defining Thromboprophylaxis in MIBC Neoadjuvant Care
-
May 13, 2026, 16:28Nadia Tarhini: Evaluating the Risk of Recurrent Thrombosis in Children with ALL
-
May 13, 2026, 16:01Sifat Jubaira: When Low MCV Meets High Platelets
-
May 13, 2026, 15:58Aktham El-rekaby: Immunothrombosis in Acute Ischaemic Stroke
-
May 13, 2026, 15:49Alison Dougall: Oral Health and Cardiovascular Risk in Bleeding Disorders
-
May 13, 2026, 15:38International Journal of Stroke: Oral Anticoagulants and DOAC–Antiplatelet Therapy Are Associated with Increased Major Bleeding Risk
-
May 13, 2026, 15:19Papa Heme։ Causes of Isolated Prolonged aPTT Without Bleeding